Aurobindo Pharma leads the gainer list of ‘BSE Health Care’ space

Aurobindo Pharma Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524804 | NSE: AUROPHARMA

21 Nov 2011 Evaluate

Aurobindo Pharma is currently trading at Rs. 84.70, up by 2.35 points or 2.85% from its previous closing of Rs. 82.35 on the BSE.

The scrip opened at Rs. 82.25 and has touched a high and low of Rs. 85.90 and Rs. 81.80 respectively. So far 3,63,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 275.00 on 05-Jan-2011 and a 52 week low of Rs. 80.35 on 18-Nov-2011.

Last one week high and low of the scrip stood at Rs. 113.65 and Rs. 80.35 respectively. The current market cap of the company is Rs. 2,465.00 crore.

The promoters holding in the company stood at 54.36% while Institutions and Non-Institutions held 31.77% and 13.87% respectively.

Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like USFDA, UKMHRA, WHO, Health Canada, MCC South Africa, TGA Australia, ANVISA Brazil.

The Company reported net loss of Rs 41.88 crore for the quarter ended September 30, 2011 as compared to net profit Rs 214.03 crore for the corresponding quarter of the previous year. Company’s total income for the second quarter of the fiscal 2011-12 has decreased by 8.89% at Rs 959.41 crore from Rs 1053.04 crore in the corresponding quarter of the fiscal 2010-11. On consolidated basis, the Group reported net loss of Rs 80.16 crore for the quarter under review as compared to net profit of Rs 198.32 crore for the quarter ended September 30, 2010. Its total income has slipped by 3.73% to Rs 1081.27 crore for the quarter ended September 30, 2011 from Rs 1123.20 crore for the quarter ended September 30, 2010.

Further, the company reported that its first half of the current fiscal has been challenging on account of lower formulation sales, full impact of the US FDA alert on its Unit VI Cephalosporin manufacturing facility, subdued demand environment in Europe, disruption in operations due to regional unrest and notional loss on restatement of foreign currency borrowings. However, the company is confident to deliver on better operational performance in the coming quarters with profitable sales mix.

The consolidated financials include results of all the subsidiaries and joint ventures. During the quarter, Aurobindo Pharma (Bulgaria), a stepdown subsidiary of the company, was liquidated and ceased to be a subsidiary

Aurobindo Pharma Share Price

1489.20 0.70 (0.05%)

11-May-2026 13:36 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1873.00
Dr. Reddys Lab	1293.10
Cipla	1321.20
Zydus Lifesciences	946.90
Lupin	2264.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.